A PROTOCOL FOR GENERATION OF FUNCTIONAL MYELOID-DERIVED SUPPRESSOR CELLS FROM EMBRYONIC STEM CELLS AND HEMATOPOIETIC STEM CELLS

To date, a major limiting factor for the use of MDSCs in certain therapies – in pathological settings where deleterious or excessive immune responses need to be avoided or reduced – is the source of MDSCs. Mount Sinai researchers demonstrated efficient in vitro derivation of MDSCs from embryonic stem cells and hematopoietic stem/progenitor cells. Together with a suite of other Mount Sinai MDSC-related technologies, this differentiation protocol poises MDSC’s to be applicable more broadly in a clinical setting.

Current Development Status

• Ongoing studies to confirm protocol in human embryonic, induced pluripotent, and hematopoietic stem cells

Applications

• Autoimmune diseases
• Graft versus host disease
• Cancer – as a delivery vehicle under appropriate clinical conditions

Advantages

• Source of cells with one week, well defined protocol to generate MDSCs which will enhance their adoption in clinical use as a therapy

Publications

• Zhou, Z, Development and Function of Myeloid-Derived Suppressor Cells Generated From Mouse Embryonic and Hematopoietic Stem Cells, Stem Cells, 2010, 28, 620-632

Patent Status

• International Application PCT/US2009/65981 filed November 25, 2009
• Status: Published. International  Publication No. WO 2010/062990
• US Application 13/131,450 filed December 15, 2011
• Status: Published. US Publication No. 2012-0082688

Contact

Jeanne Farrell, PhD
Business Development Director
Mount Sinai Innovation Partners | Icahn School of Medicine at Mount Sinai
Phone: 646.605.7314